Provectus Biopharmaceuticals PVCT
OTC PVCT
$0.05 +0.00 (+0.00%)
At close: Oct 21, 2026 · 4:00 PM EDT

Provectus Biopharmaceuticals (PVCT) Cash from Financing Activities (2010 - 2025)

Updated

Provectus Biopharmaceuticals (PVCT) posted Cash from Financing Activities of $1.05 million for Q4 2025, up 33.0% from $788,419 a year earlier and up 111.4% from the prior quarter.

Analysis

Provectus Biopharmaceuticals (PVCT) Cash from Financing Activities (2010 - 2025) Analysis & Trends

For FY2025, Provectus Biopharmaceuticals' Cash from Financing Activities came in at $3.09 million, up 12.3% from FY2024.

  • Annual Cash from Financing Activities has increased for three consecutive years, though with a five-year compound annual growth rate of -3.0% (FY2020 to FY2025).
  • In prior years, Provectus Biopharmaceuticals' Cash from Financing Activities was $2.75 million in FY2024 (+25.4%), $2.19 million in FY2023 (+60.2%), $1.37 million in FY2022 (-66.0%) and $4.02 million in FY2021 (+11.8%).
  • Quarterly Cash from Financing Activities has run from a low of -$33,527 in Q1 2022 to a high of $1.37 million in Q1 2021 over five years.
  • On a year-over-year basis, Cash from Financing Activities increased in four of the last eight quarters, with growth averaging 42.3%.
  • The strongest year-over-year quarter for Cash from Financing Activities in the past five years was Q1 2021, with growth of 298.5%; the weakest was Q2 2021, with a decline of 81.9%.
  • According to Business Quant data, Cash from Financing Activities for the three prior quarters was $495,903 (Q3 2025), $469,759 (Q2 2025) and $1.07 million (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 8.43 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn -8.53 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -5.05 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 1.76 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -2.02 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn -3.89 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -1.48 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 2.34 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -3.66 Bn
10 Provectus Biopharmaceuticals 21.01 Mn 19.10 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 1.05 Mn
Sep 30, 2025 495,903.00
Jun 30, 2025 469,759.00
Mar 31, 2025 1.07 Mn
Dec 31, 2024 788,419.00
Sep 30, 2024 589,399.00
Jun 30, 2024 588,952.00
Mar 31, 2024 781,095.00
Dec 31, 2023 201,552.00
Sep 30, 2023 817,859.00
Jun 30, 2023 656,441.00
Mar 31, 2023 515,703.00
Dec 31, 2022 474,158.00
Sep 30, 2022 496,868.00
Jun 30, 2022 430,342.00
Mar 31, 2022 -33,527.00
Dec 31, 2021 1.23 Mn
Sep 30, 2021 1.02 Mn
Jun 30, 2021 404,292.00
Mar 31, 2021 1.37 Mn
API Access

Provectus Biopharmaceuticals Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=PVCT&period=max&api_key=YOUR_API_KEY